Skip to main content

2024 HFSA CME Symposium - Treating Hyperkalemia in Patients with Heart Failure: Making the Right Choices

By: PRLog

This CME Symposium takes place on Saturday, September 28, 2024 from 7:30 - 8:45 AM ET during the 2024 Heart Failure Society of America (HFSA) Annual Scientific Meeting at the Signia by Hilton Atlanta in Atlanta, Georgia in the Triumph Ballroom G.

HAZLET, N.J. - Aug. 12, 2024 - PRLog -- In this program, experts will 1) identify HF medications that increase the risk for hyperkalemia, 2) emphasize the importance of patients taking RAASi therapy and at target doses, 3) discuss the clinical evidence for using novel potassium binders for the treatment of hyperkalemia, and their potential impact in facilitating optimization of RAASi therapy to reduce patient cardiovascular risk, and 4) explain the rationale for using novel potassium binders in long-term management.

The educational objectives include:

  • Recognize hyperkalemia as a frequent, treatable, and manageable side effect of optimal HF therapy
  • Describe the relationship between down-titration or discontinuation of RAASi therapy and clinical outcomes
  • Discuss the clinical evidence for novel potassium binders in the treatment of hyperkalemia
Click here for more information

CHAIR
Mikhail Kosiborod, MD

Vice President of Research
Saint Luke's Health System
Professor of Medicine
University of Missouri-Kansas City
Kansas City, Missouri

FACULTY
Akshay Desai, MD, MPH

Director, Cardiomyopathy and Heart Failure Program
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Anuradha Lala-Trindade, MD
Associate Professor of Medicine
Associate Professor of Population Health Science and Policy
Ichan School of Medicine at Mount Sinai
New York, New York

Orly Vardeny, PharmD
Associate Professor of Medicine
University of Minnesota
Medical School
Minneapolis, Minnesota

This educational activity is intended for clinicians who manage patients with heart failure.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia LLC designates this live activity for a maximum of 1.25 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1.25 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Contact
Voxmedia
***@voxmedia.us

Photos: (Click photo to enlarge)

Voxmedia Logo 2024 HFSA CME Symposium


Source: CMEPlanet

Read Full Story - 2024 HFSA CME Symposium - Treating Hyperkalemia in Patients with Heart Failure: Making the Right Choices | More news from this source

Press release distribution by PRLog
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.